Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 247.89 is 32% below its estimated 1-year average of 364.91, near the low end of its estimated 1-year range (170.07–641.50).
As of 2026-10-06T15:03:32.118Z.
Calculation as of: 2026-10-06T15:03:32.118Z.
Quote observation: 2026-10-06T14:54:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0a8ac43d83dffe882666147bba78c75a2aa07862642b14baa2694f769a95b4c3
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
247.89
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.02
median of 430 covered companies
CURRENT VS SECTOR MEDIAN
+6066.42%
vs the sector median at left
Market Cap
$5.21M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.26M
PS Ratio
1.25
TTM Avg
1.37
3Y Avg
1.98
5Y Avg
32.27
Market Cap
$5.01M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.70M
PS Ratio
2.53
TTM Avg
15.60
3Y Avg
53.90
5Y Avg
53.90
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.19M | 247.89 | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | 1.25 | 1.37 | 1.98 | 32.27 |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A | 52.54 | 81.05 | 85.82 |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | N/A | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.54M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.70M | 2.53 | 15.60 | 53.90 | 53.90 |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.73M | 24.36 | 40.33 | 58.43 | 54.62 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2024Period ended 2025-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-06-30 |
| Q1 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q2 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q3 FY2025Period ended 2026-03-31 | $20,942 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| TTM revenue | $20,942 |
Current P/S: $5,191,304 market capitalization ÷ $20,942 TTM revenue = 247.89x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:54:40.000Z. Latest revenue period ended 2026-03-31.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
At 247.89, P/S is at an extreme level, where the multiple carries little signal — higher than 4% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
170.07
median
355.07
estimated 1-year high
641.50
P/S Ratio
247.89
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 170.07 |
| 2026-10-02 | 193.94 |
| 2026-10-01 | 205.88 |
| 2026-09-30 | 219.30 |
| 2026-09-29 | 264.06 |
| 2026-09-28 | 277.49 |
| 2026-09-25 | 287.93 |
| 2026-09-24 | 289.42 |
| 2026-09-23 | 319.26 |
| 2026-09-22 | 332.69 |
| 2026-09-21 | 343.13 |
| 2026-09-18 | 347.61 |
| 2026-09-17 | 340.15 |
| 2026-09-16 | 323.74 |
| 2026-09-15 | 326.72 |
| 2026-09-14 | 323.74 |
| 2026-09-11 | 355.07 |
| 2026-09-10 | 364.02 |
| 2026-09-09 | 389.38 |
| 2026-09-08 | 387.89 |
| 2026-09-04 | 356.56 |
| 2026-09-03 | 350.59 |
| 2026-09-02 | 358.05 |
| 2026-09-01 | 320.75 |
| 2026-08-31 | 340.15 |
| 2026-08-28 | 353.57 |
| 2026-08-27 | 350.59 |
| 2026-08-26 | 358.05 |
| 2026-08-25 | 328.21 |
| 2026-08-24 | 317.77 |
| 2026-08-21 | 320.75 |
| 2026-08-20 | 328.21 |
| 2026-08-19 | 331.20 |
| 2026-08-18 | 323.74 |
| 2026-08-17 | 335.67 |
| 2026-08-14 | 331.20 |
| 2026-08-13 | 334.18 |
| 2026-08-12 | 350.59 |
| 2026-08-11 | 358.05 |
| 2026-08-10 | 352.08 |
| 2026-08-07 | 359.54 |
| 2026-08-06 | 361.03 |
| 2026-08-05 | 369.98 |
| 2026-08-04 | 380.43 |
| 2026-08-03 | 356.56 |
| 2026-07-31 | 289.42 |
| 2026-07-30 | 301.36 |
| 2026-07-29 | 314.78 |
| 2026-07-28 | 334.18 |
| 2026-07-27 | 332.69 |
| 2026-07-24 | 347.61 |
| 2026-07-23 | 346.11 |
| 2026-07-22 | 389.38 |
| 2026-07-21 | 411.76 |
| 2026-07-20 | 393.85 |
| 2026-07-17 | 420.71 |
| 2026-07-16 | 429.66 |
| 2026-07-15 | 444.58 |
| 2026-07-14 | 444.58 |
| 2026-07-13 | 422.20 |
| 2026-07-10 | 438.61 |
| 2026-07-09 | 407.28 |
| 2026-07-08 | 408.77 |
| 2026-07-07 | 420.71 |
| 2026-07-06 | 460.99 |
| 2026-07-02 | 477.40 |
| 2026-07-01 | 460.99 |
| 2026-06-30 | 487.84 |
| 2026-06-29 | 472.92 |
| 2026-06-26 | 478.89 |
| 2026-06-25 | 531.11 |
| 2026-06-24 | 511.71 |
| 2026-06-23 | 641.50 |
| 2026-06-22 | 619.13 |
| 2026-06-18 | 563.93 |
| 2026-06-17 | 596.75 |
| 2026-06-16 | 425.18 |
| 2026-06-15 | 389.38 |
| 2026-06-12 | 359.54 |
| 2026-06-11 | 372.97 |
| 2026-06-10 | 337.16 |
| 2026-06-09 | 341.64 |
| 2026-06-08 | 353.57 |
| 2026-06-05 | 365.51 |
| 2026-06-04 | 435.63 |
| 2026-06-03 | 428.17 |
| 2026-06-02 | 444.58 |
| 2026-06-01 | 441.59 |
| 2026-05-29 | 459.50 |
| 2026-05-28 | 453.53 |
| 2026-05-27 | 390.87 |
| 2026-05-26 | 314.78 |
| 2026-05-22 | 337.16 |
| 2026-05-21 | 346.11 |
| 2026-05-20 | 268.54 |
| 2026-05-19 | 298.37 |
| 2026-05-18 | 308.82 |
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.